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We evaluated highly sensitive methods using boronic acid (BA) to detect extended-spectrum -lacta-
mase (ESBL) production. A total of 182 clinical isolates of Klebsiella spp. (n  118) and Escherichia coli
(n  64) were analyzed: 62 harbored only ESBLs, 80 harbored both ESBLs and plasmid-mediated AmpC
-lactamases (pAmpCs), and 40 harbored only pAmpCs. The CLSI confirmatory test detected all isolates
that produce only ESBLs but detected 85% of isolates that produce both enzymes. When a >5-mm increase
in the zone diameter of either the cefotaxime (CTX) or the ceftazidime (CAZ) disk in the presence of both
clavulanic acid (CA) and BA was considered to be a positive result, the test detected all isolates that
harbor ESBLs ( pAmpCs) but showed frequent false-positive results (50%) for isolates that produce only
pAmpCs. Meanwhile, when a >3-mm increase in the zone diameter of either the CTX/BA or the CAZ/BA
disk in the presence of CA was considered to be a positive result, the test also detected all isolates that
harbor ESBLs ( pAmpCs) and showed less frequent false-positive results (5%) in isolates that produce
only pAmpCs. The latter new interpretive guideline has enhanced detection of ESBLs in clinical isolates
of Klebsiella spp. and Escherichia coli and allowed detection of an ESBL even when potentially masked by
a pAmpC.
Since extended-spectrum -lactamases (ESBLs) were ini-
tially reported to be in Klebsiella ozaenae in the first half of the
1980s in Germany, ESBLs have been spreading globally (2).
The CLSI interpretive guidelines stated that strains of Kleb-
siella spp. and Escherichia coli that produce ESBLs may be
clinically resistant to therapy with penicillins, cephalosporins,
or aztreonam, despite apparent in vitro susceptibility to some
of these agents (4). Therefore, detection of ESBLs in Klebsiella
spp. and E. coli isolates is crucial for optimal treatment of
patients and to control the spread of resistance. The CLSI
recommends a phenotypic confirmatory test for ESBL produc-
tion that consists of measuring the zone diameters of cefo-
taxime (CTX; 30 g) or ceftazidime (CAZ; 30 g) disks with
or without clavulanic acid (CA; 10 g) in Klebsiella spp. and E.
coli. An increase in the zone diameter of 5 mm in the pres-
ence of CA is taken to be a phenotypic confirmation of ESBL
production.
There are numerous reports in which Klebsiella pneumoniae
and E. coli isolates have been found to produce both plasmid-
mediated AmpC -lactamases (pAmpCs) and ESBLs (6, 8). In
Korea, 8.7% of pAmpC producers also produced ESBLs (8).
AmpCs resist inhibition by CA, and hence, the presence of an
ESBL can be masked by the expression of an AmpC. Thus, the
coexistence of both pAmpCs and ESBLs in the same strain
may result in false-negative tests for the detection of ESBLs
(5). There is a need, therefore, for an alternative method that
can detect ESBLs in Klebsiella spp. and E. coli isolates with a
high sensitivity, even though the isolates simultaneously harbor
pAmpCs.
Boronic acids (BAs) were reported as reversible inhibitors of
AmpCs (1). There are a few reports of studies designed to
detect pAmpC-producing isolates of Klebsiella spp. and E. coli
by a method using BA as an inhibitor that closely resembles the
phenotypic confirmatory tests for ESBLs (3, 5). And Coudron
(5) recently described that a BA disk also enhances detection
of isolates that harbor both ESBLs and pAmpCs.
The aim of this work was to modify the phenotypic confir-
matory test for ESBL production by using BA disks to improve
its sensitivity for the detection of ESBLs in Klebsiella spp. and
E. coli isolates even though the isolates simultaneously harbor
pAmpCs.
MATERIALS AND METHODS
Bacterial strains. A total of 182 nonrepeat ESBL- and/or pAmpC-producing
clinical isolates of Klebsiella spp. (n  118) and E. coli (n  64) collected from
12 tertiary-care hospitals in Korea during 2004 and 2005 were included in this
study (Table 1): 62 harbored ESBLs but not pAmpCs, 80 harbored both ESBLs
and pAmpCs, and 40 harbored pAmpCs but not ESBLs. The isolates were
identified with API-20 E systems (bioMe´rieux, Marcy l’Etoile, France). Searches
for genes coding for the class A ESBLs and pAmpCs were performed by PCR
amplification as described previously (7, 8). The PCR products were subjected to
direct sequencing. Both strands of each PCR product were sequenced twice with
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an automatic sequencer (model 3730xl; Applied Biosystems, Weiterstadt, Ger-
many).
ESBL detection by the CLSI confirmatory test and two different tests using BA.
Disks containing BA were produced in-house by using commercially available
antibiotic-containing disks (BBL, Cockeysville, MD) as described previously
(5). Briefly, 20 l of the 3-aminophenyl BA stock solution (20 g/liter; Sigma,
St. Louis, MO) was dispensed onto each disk containing CTX (30 g) or CAZ
(30 g) with or without CA (10 g). The final amount of BA on the disks was
400 g. The disks were allowed to dry for 60 min and used immediately or
stored in airtight vials with desiccant at 4°C. The CLSI confirmatory test for
ESBL production was carried out on Mueller-Hinton agar (Difco Laborato-
ries, Detroit, MI) by using antibiotic-containing disks with or without CA. In
two new different tests using BA (400 g), (i) a 5-mm increase in the zone
diameter of the disk containing CTX (and/or CAZ) and CA tested in com-
bination with BA (CTX/CA/BA and/or CAZ/CA/BA) versus CTX and/or
CAZ alone was considered positive for ESBL, and (ii) a 3-mm increase in
the zone diameter of the disk containing CTX (and/or CAZ) and CA tested
in combination with BA (CTX/CA/BA and/or CAZ/CA/BA) versus CTX
and/or CAZ containing BA (CTX/BA and/or CAZ/BA) was considered pos-
itive for ESBL. CTX, CTX/CA, CAZ, and CAZ/CA disks with or without BA
were spaced over the agar surface. After overnight incubation at 35°C in
ambient air, the inhibitory-zone diameters of the antibiotic-containing disks
were measured.
RESULTS AND DISCUSSION
All 62 clinical isolates that produce ESBLs but not pAmpCs
showed 5-mm increases in the zone diameters of the com-
bined disks (CTX [or CAZ]/CA or CTX [or CAZ]/CA/BA)
compared with those for CTX or CAZ alone (Table 2). The
average increases in the zone diameters of the CTX and CAZ
disks in the presence of both CA and BA (13.1 mm and 12.6
mm, respectively) were higher than those for the CLSI confir-
matory test (11.3 mm and 10.9 mm, respectively). In tests with
CA, the CTX and CAZ disks yielded positive tests with 60
(96.8%) and 58 (93.5%) of 62 isolates, respectively (Fig. 1A
and B). In tests with both CA and BA, the CTX and CAZ disks
yielded positive tests with 61 (98.4%) and 62 (100%) of 62
isolates, respectively (Fig. 1C and D). Meanwhile, all 62 clin-
ical isolates showed 3-mm increases in the zone diameters of
both the CTX/BA and the CAZ/BA disks in the presence of
CA, with the exception of a K. pneumoniae isolate that pro-
duces SHV-2a, which showed a 2-mm increase in the zone
diameter of a CAZ/BA disk in the presence of CA (Fig. 1E and
F). The average increases in the zone diameters of the
CTX/BA and CAZ/BA disks in the presence of CA were 11.8
mm and 11.1 mm, respectively.
The rate of detection of ESBLs by the CLSI confirmatory
TABLE 1. Bacterial strains used for the validation of test methods
Strain group and genotype(s)
No. of strains
Klebsiella
spp. E. coli Total
Producing ESBLs but not pAmpCs
blaCTX-M-3 1 2 3
blaCTX-M-3 plus blaCTX-M-14 1 1
blaCTX-M-9 1 1
blaCTX-M-14 8 8
blaCTX-M-15 11 11
blaCTX-M-15 plus blaSHV-2a or blaSHV-12 5 5
blaSHV-2a 1 1
blaSHV-12 28 2 30
blaTEM-52 2 2
Subtotal 31 31 62
Producing both ESBLs and pAmpCs
blaCTX-M-3 plus blaCMY-10 or blaDHA-1 1 2 3
blaCTX-M-3 plus blaSHV-12 plus blaDHA-1 4 4
blaCTX-M-9 plus blaCMY-2 or blaDHA-1 3 3
blaCTX-M-9 plus blaSHV-2a or blaSHV-12 plus
blaDHA-1
1 1 2
blaCTX-M-12 plus blaSHV-12 plus blaDHA-1 1 1
blaCTX-M-14 plus blaCMY-2 or blaDHA-1 1 7 8
blaCTX-M-15 plus blaCMY-2 2 2
blaCTX-M-15 plus blaSHV-12 plus blaDHA-1 1 1
blaSHV-12 plus blaCMY-2 or blaDHA-1 56 56
Subtotal 64 16 80
Producing pAmpCs but not ESBLs
blaCMY-1 3 4 7
blaCMY-2 1 6 7
blaCMY-10 1 1 2
blaDHA-1 18 6 24
Subtotal 23 17 40
Total 118 64 182
TABLE 2. Test results for the 182 ESBL- and/or pAmpC-producing
clinical isolates of Klebsiella spp. (n  118) and E. coli (n  64)
Strain group
and species
No. (%) of isolates that showed positive
results for indicated testa:
CLSI
confirmatoryb
CTX/CA/BA
vs CTX and/
or CAZ/CA/
BA vs CAZc
CTX/CA/
BA vs CTX/BA
and/or CAZ/
CA/BA vs CAZ/
BAd
Producing ESBLs but not
pAmpCs
Klebsiella spp. (n  31) 31 (100) 31 (100) 31 (100)
E. coli (n  31) 31 (100) 31 (100) 31 (100)
Subtotal (n  62) 62 (100) 62 (100) 62 (100)
Producing both ESBLs
and pAmpCs
Klebsiella spp. (n  64) 55 (86) 64 (100) 64 (100)
E. coli (n  16) 13 (81) 16 (100) 16 (100)
Subtotal (n  80) 68 (85) 80 (100) 80 (100)
Producing pAmpCs but
not ESBLs
Klebsiella spp. (n  23) 3 (13) 9 (39) 1 (4)
E. coli (n  17) 3 (18) 11 (65) 1 (6)
Subtotal (n  40) 6 (15) 20 (50) 2 (5)
a Abbreviations: CTX, cefotaxime; CAZ, ceftazidime; CA, clavulanic acid;
BA: boronic acid.
b The zone diameter of the disk containing CTX (or CAZ) and CA was 5
mm greater than that of the disk containing CTX (or CAZ).
c The zone diameter of the disk containing CTX (or CAZ), CA, and BA was
5 mm greater than that of the disk containing CTX (or CAZ).
d The zone diameter of the disk containing CTX (or CAZ), CA, and BA was
3 mm greater than that of the disk containing CTX (or CAZ) and BA.
VOL. 45, 2007 DETECTION OF ESBLs BY USING BA 1181
test for clinical isolates that produce both ESBLs and pAmpCs
was lower than that for clinical isolates that produce ESBLs
but not pAmpCs (Table 2). Among 80 clinical isolates that
produce both ESBLs and pAmpCs, 68 (85%) showed 5-mm
increases in the zone diameters of either the CTX or the CAZ
disks in the presence of CA. In this test, the CTX and CAZ
disks yielded positive tests with 51 (63.8%) and 45 (56.3%) of
80 isolates, respectively (Fig. 1A and B). All 80 clinical isolates,
however, showed 5-mm increases in the zone diameters of
either the CTX or the CAZ disks in the presence of both CA
and BA (Table 2). In this test, CTX and CAZ disks yielded
positive tests with 80 (100%) and 75 (93.8%) of 80 isolates,
respectively (Fig. 1C and D). The average increases in the zone
diameters of the CTX and CAZ disks in the presence of both
CA and BA (11.9 mm and 9.9 mm, respectively) were higher
than those for the CLSI confirmatory test (7.1 mm and 5.1 mm,
FIG. 1. Comparison of the results for the CLSI confirmatory test (A and B) and two new tests (C to F). The abbreviations (CTX/CA versus
CTX, CAZ/CA versus CAZ, CTX/CA/BA versus CTX, CAZ/CA/BA versus CAZ, CTX/CA/BA versus CTX/BA, and CAZ/CA/BA versus
CAZ/BA) are explained in footnote a to Table 2. Black circle, Klebsiella spp.; white circle, E. coli.
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respectively). All 80 clinical isolates also showed 3-mm in-
creases in the zone diameters of either the CTX/BA or the
CAZ/BA disks in the presence of CA (Table 2). In this test, 76
(95%) and 68 (85%) of 80 isolates showed3-mm increases in
the zone diameters of the CTX/BA and CAZ/BA disks in the
presence of CA, respectively (Fig. 1E and F). The average
increases in the zone diameters of the CTX/BA and CAZ/BA
disks in the presence of CA were 8.7 mm and 7.9 mm, respec-
tively.
Among the 40 clinical isolates that produce pAmpCs but not
ESBLs, 6 (15%) and 20 (50%) isolates showed 5-mm in-
creases in the zone diameters of either the CTX or the CAZ
disks in the presence of CA and both CA and BA, respectively
(Table 2). Meanwhile, only 2 (5%) of the 40 isolates showed
3-mm increases in the zone diameters of either the CTX/BA
or the CAZ/BA disks in the presence of CA (Table 2).
In summary, the CLSI confirmatory test detected ESBLs in
all clinical isolates that produce ESBLs but not pAmpCs, but
the detection rate (85%) was lowered in clinical isolates that
produce both ESBLs and pAmpCs. The test showed false-
positive results in 6 (15%) of 40 clinical isolates that produce
pAmpCs but not ESBLs. When a 5-mm increase in the zone
diameter of either the CTX or the CAZ disk in the presence of
both CA and BA was considered to be a positive result for
ESBL production, the new test detected all clinical isolates
that harbor ESBLs ( pAmpCs) but showed frequent false-
positive results (20/40, 50%) for clinical isolates that pro-
duce pAmpCs but not ESBLs. An inhibitory effect of BA on
pAmpCs may have an influence on the high frequency of
false-positive results. Meanwhile, when a 3-mm increase in
the zone diameter of either the CTX/BA or the CAZ/BA disk
in the presence of CA was considered to be a positive result for
ESBL production, the test also detected all clinical isolates that
harbor ESBLs ( pAmpCs) and the test showed less frequent
false-positive results (2/40, 5%) for clinical isolates that pro-
duce pAmpCs but not ESBLs. In the case of the CTX/BA disk
in the presence of CA, there were no false-positive results (Fig.
1E). The test missed none of the ESBL-producing isolates.
Coudron (5) recently reported that a BA-based method using
cefotetan enhanced detection of pAmpCs, but Coudron’s
method missed one of the pAmpC-producing Proteus mirabilis
isolates. Although Coudron reported that the method can also
detect isolates harboring pAmpCs and ESBLs, only three iso-
lates were tested for the presence of both enzymes, and they
did not include E. coli isolates.
In conclusion, we describe a newly modified method with a
high sensitivity and a high specificity for the detection of
ESBLs in clinical isolates of Klebsiella spp. and E. coli. A
3-mm increase in the zone diameter of either the CTX/BA or
the CAZ/BA disk in the presence of CA is a new interpretive
guideline that has enhanced detection of ESBLs in clinical
isolates of Klebsiella spp. and E. coli and allowed detection of
an ESBL even when potentially masked by a pAmpC. The
exact detection of ESBLs in isolates that produce both ESBLs
and pAmpCs is important for both treatment and
epidemiology.
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